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Abstract
Purpose—Whether and how to return individual genetic results to study participants is among
the most contentious policy issues in contemporary genomic research.
Methods—We surveyed corresponding authors of genome-wide association studies (GWAS),
identified through the National Human Genome Research Institute's Catalog of Published GWAS,
to describe the experiences and attitudes of these stakeholders.
Results—Of 357 corresponding authors, 200 (56%) responded. One hundred twenty-six (63%)
had been responsible for primary data and sample collection, whereas 74 (37%) had performed
secondary analyses. Only 7 (4%) had returned individual results within their index GWAS. Most
(69%) believed that return of results to individual participants was warranted under at least some
circumstances. Most respondents identified a desire to benefit participants's health (63%) and
respect for participants's; desires for information (57%) as major motivations for returning results.
Most also identified uncertain clinical utility (76%), the possibility that participants will
misunderstand results (74%), the potential for emotional harm (61%), the need to ensure access to
trained clinicians (59%), and the potential for loss of confidentiality (51%) as major barriers to
return.
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tConclusion—Investigators have limited experience returning individual results from genome-
scale research, yet most are motivated to do so in at least some circumstances.
Introduction
Through genome-wide association studies (GWAS), investigators have identified thousands
of single nucleotide polymorphisms (SNPs) associated with a variety of diseases.1 Although
most of these variants have modest relationship to disease risk, a subset of SNPs correspond
to available clinical tests.2 In this context, a discussion has emerged about the ethics of
returning individual genetic results to research participants.3-6 While participant preferences
are not the only factor that should determine policies, data suggest that most participants
desire results.7-9 Furthermore, guidelines support the return of non-genetic incidental
findings, such as those encountered in neuroimaging research, at least when the findings
have immediate clinical significance.10-12 Finally, although some commentators
disagree13-15, guidelines recommend that a limited set of individual genetic results with
clear clinical validity and utility should be returned to participants who have indicated
during the consent process that they desire to receive such results.4,16,17
Genome investigators are critical stakeholders in this debate. However, evidence about their
attitudes and practices is limited.18,19 We therefore surveyed corresponding authors of
published GWAS in order to describe their perspectives and experiences with returning
individual genetic research results.
Materials and Methods
Survey Instrument
We reviewed published work on the return of individual genetic results to research
participants to develop a draft questionnaire. The draft survey consisted of four sections:
demographics and work characteristics, study characteristics and roles, study practices, and
views. When providing information about study characteristics, roles and practices,
respondents were directed to consider the particular study on the basis of which they were
identified for this survey. The survey was revised following face validity assessment by two
genetic/genomic epidemiology researchers who were not eligible for participation in the
study.
Study Population, Recruitment, and Survey Administration
Eligible investigators were identified through the National Human Genome Research
Institute's (NHGRI) Catalog of Published GWAS (accessed April 15, 2010).20 When an
individual was corresponding author on more than one study, he or she was contacted with
reference to the most recent publication. Data collection occurred between October 2010 and
February 2011.
Investigators were contacted up to five times to participate in the survey. An initial and two
follow up invitations were sent via publicly available email addresses with a link to the
online survey. The online survey was administered using a web-based survey self-
administration system (Illume, DatStat Inc., Seattle, WA). The penultimate contact included
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ta letter and paper version of the survey sent via US Postal Service or Federal Express to
nonrespondents to the follow up emails. The final contact to nonresponders was via email
with a link to the online survey.
The study was approved by the Institutional Review Boards (IRBs) at the Dana-Farber
Cancer Institute and the Baylor College of Medicine.
Statistical Analysis
Stata 10 (Stata Corp., College Station, Texas) was used to perform appropriate descriptive
statistical analyses and hypothesis tests. Chi-square tests were used to evaluate associations
between categorical variables. Mann-Whitney U tests were used to assess the relationship
between independent variables and ordinal outcome variables, such as the degree to which
respondents perceived various factors as barriers to or motivations for return of results. In all
analyses, statistical significance was declared if 2-sided p values were <0.05.
Results
Characteristics of respondents and of index GWAS
Of 360 unique corresponding authors eligible to take part in the survey, contact information
was unavailable for three. Of the remaining 357, 200 responded (response rate 56%; 191
responses were complete). Respondents' demographic and professional characteristics are
shown in Table 1; most were male and self-identified as white.
Among responding investigators, 62 (31%) had published their GWAS in Nature Genetics,
12 (6%) in the American Journal of Human Genetics, and 11 (5.5%) in PLoS Genetics. No
other journal accounted for more than 5% of responses.
Respondents did not differ from non-respondents by journal in which the index GWAS was
published or by region of origin; other characteristics were unavailable for non-respondents.
The characteristics of the index GWAS on the basis of which investigators were selected are
shown in Table 2. Almost two-thirds of respondents reported that their study included
primary collection of data and specimens, whereas 37% reported conducting secondary
analyses using data and specimens obtained from another investigator or from a repository.
Among those conducting secondary analyses, most had signed a data use agreement with the
original collectors or repository, and most agreements forbade efforts at re-identifying
participants. Regardless of whether the studies involved primary data and specimen
collection or secondary analyses, most maintained links between the data and specimens and
the identities of the individual participants using a code.
Only seven respondents (4%) indicated that they had returned results to individual
participants in the context of their index GWAS. Of the remaining respondents, only two
(1%) had plans to do so. Of the nine investigators who had returned results or had plans to
do so, all had been responsible for primary collection of data and samples; none had
performed secondary analyses on data or samples collected by others. Most who had
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treturned results (N=5) did so directly to participants or their proxies, rather than through the
participant's physician.
Investigators' attitudes regarding return of results
Most respondents (n=134, 69%) believed that the return of research results to individual
GWAS participants was warranted under at least some circumstances. The belief that return
of individual research results is warranted in at least some circumstances was generally
unassociated with demographic and professional characteristics. There were no significant
associations between believing that individual genetic results should be returned in at least
some circumstances and holding an MD degree (p=0.48), having served on an IRB (p=0.84),
having interacted directly with participants (p=0.31), or having been responsible for primary
data or specimen collection (p=0.79).
Respondents endorsed several factors as major motivations to return individual genetic
research results (Figure 1). Most identified a desire to benefit participants' health (63%) and
respect for participants' desire to have information about themselves (57%) as major
motivations for returning individual results. Many (42%) also identified the belief that
participants have a right to their data as a major motivation. However, respondents also
reported a wide range of barriers to returning results (Figure 2). Most viewed the uncertain
clinical utility of genetic research results (76%), the possibility that participants will
misunderstand the information they are given (74%), the potential for emotional harm to
participants (61%), the need to ensure access to an appropriately trained clinician (59%), and
the potential for loss of confidentiality (51%) as major barriers to the return of results.
We sought to understand what attitudes and concerns distinguished investigators who
believed that individual genetic results should be returned in at least some circumstances
from those who believed they should generally not be returned. Investigators who believed
that results should generally not be returned viewed the potential for loss of patient
confidentiality (p=0.004), the possibility that participants will misunderstand the
information that they are given (p=0.009), the potential for causing emotional harm to
participants (p=0.011), and the potential to blur the boundary between research and clinical
care (p=0.002) as greater barriers than those who believed that results should be returned
under at least some circumstances. We also noted numerous differences between these two
groups of investigators with respect to the motivations that they endorsed. Investigators who
believed that results should be returned in some circumstances were more likely than those
who did not share this belief to endorse the desire to benefit participants' health (p=0.003),
respect for participants' desires to have information about themselves (p=0.002), the view
that participants have a right to their data (p=0.0002), concern over legal liability if
individual results are not disclosed (p=0.016), and gratitude to participants for taking part in
the study (p=0.0008) as motivations for offering to return results.
Investigators who had been responsible for primary collection of data and samples and those
who had performed secondary analyses of data or samples collected by others endorsed
different barriers to and motivations for returning results. Those who had performed
secondary data analyses perceived the time commitment required to return results (p=0.029),
the need to keep contact information current (p=0.054), and the need to use a clinically
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tcertified lab (p=0.007) as greater barriers to the return of individual results. Those
responsible for primary data collection, in contrast, viewed the desire to benefit participants'
health as a greater motivation to return results (p=0.008).
Discussion
We surveyed corresponding authors of published GWAS to clarify their experiences with
and attitudes towards return of individual results and incidental findings from genome-scale
studies. Few respondents reported experience with returning individual results, at least
within their index GWAS. This observation suggests that investigators may be unprepared
for the challenges posed by whole-exome and whole-genome sequencing studies, which will
identify clinically relevant incidental findings more frequently than do GWAS.21-23 In
qualitative interviews, however, we observed that many genome investigators report having
returned results identified through other study designs, including linkage and family
studies.24 Although linkage and family designs differ in numerous ways from sequencing-
based approaches, this experience may be helpful as investigators consider whether and how
to return incidental findings uncovered by sequencing research.
Not with standing their lack of personal experience returning results from genome-scale
studies, most respondents reported believing that return of individual genetic research results
may be warranted under at least some circumstances. Major motivations cited by
respondents for returning results included a desire to benefit participants' health and respect
for participants' desires for information about themselves. Major barriers included the
uncertain clinical utility of results, the possibility that participants might misunderstand
information, the potential for emotional harm, the need to ensure access to appropriately
trained clinicians, and the potential for loss of confidentiality.
Respondents who believed that individual results should generally not be offered to research
participants differed from those who believed that results should at least sometimes be
offered with respect to the motivations and barriers that they cited. In particular, they were
more likely to identify beneficence-based concerns, such as loss of confidentiality, the
possibility that participants would misunderstand the information, and the potential for
emotional harm. Notably, respondents who believed that results should generally not be
offered were not more likely than other respondents to identify logistical barriers to return,
including the need to ensure access to a trained clinician, the need to use a clinically
certified lab, the time and costs involved, or the need to keep contact information current.
Respondents who had been responsible for primary specimen and data collection identified
different barriers and motivations as compared with those who had conducted secondary
analyses of specimens and data collected by others. These differences may reflect closer
interactions between investigators responsible for primary specimen and data collection and
the participants in their studies, or may derive from these investigators' greater ability to
provide results through established contact pathways.
Few previous studies have addressed researchers' perspectives on return of results. Among
19 GWAS investigators interviewed by Williams and colleagues, few had experience
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treturning results. Investigators generally emphasized reasons not to return results, but felt
compelled to disclose “when research resulted in genomic incidental findings with clear or
probable medical significance.”19 Meacham et al presented 44 investigators who had
received federal funding to conduct human subjects research, not limited to genomic
research, with a hypothetical scenario involving identification of a genetic variant associated
with a “high risk” of developing colorectal cancer.18 Most investigators said they would
offer the results to participants, and identified ensuring high-quality information, the need to
minimize harm to participants, and adherence to IRB and other rules as their principal
concerns in deciding about return. Our study supports the observations of this previous work
while extending the findings to a large, representative, international sample of genome
investigators.
Although we cannot directly compare the views of investigators reported here to those of
other stakeholder groups, some generalizations are possible. In most previous studies of
participants or members of the public, a higher proportion of respondents than we observed
among investigators—generally 80-90%—indicate a desire for access to individual results.8
Participants are also more likely to enroll in studies when they have access to results.7 In
qualitative studies, most IRB representatives also indicate support for return of results with
definite clinical utility while expressing concern about the possibility of returning
unvalidated results.19,25 Our data suggest that most investigators share with IRB
representatives both a willingness to return results in select circumstances and a recognition
of the numerous concerns and caveats surrounding the move towards offering results.
The study reported here has limitations. First, the experiences and attitudes of non-
respondents may differ from those of survey respondents. Although respondents and non-
respondents were similar with respect to region of origin and journal in which their index
GWAS was published, we lacked other data on non-respondents and therefore could not
comprehensively compare the characteristics of respondents to those of non-respondents.
Second, the issues addressed in this survey are complex, and the survey questions may not
have fully captured investigators' perspectives. Follow-up qualitative interviews, reported
separately, provide additional insights into the views of genome investigators regarding
return of results.24
In conclusion, investigators have limited experience returning individual results identified in
the course of genome-scale research, yet most are motivated to do so in at least some
circumstances. Given the rapid transition of research from genotyping of common variants
to sequencing for rare, potentially highly penetrant variants, and in light of policy guidance
suggesting that offering results is sometimes ethically required4,16,17,26, the need to develop
mechanisms to facilitate the return of results has become urgent. To be successful, such
mechanisms must address the concerns identified by the genome researchers who will be
responsible for implementing them in practice.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Motivations for the return of individual genetic research results among GWAS
investigators
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tFigure 2. Barriers to the return of individual genetic research results among GWAS
investigators
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Table 1
Characteristics of respondents
Characteristic (n=200*) Number (Percent)
Age, mean (standard deviation, range) 47.5 (8.7, 26-74)
Female 58 (29%)
Race
  Asian 36 (18%)
  Black or African American 1 (1%)
  White 152 (77%)
  Other 9 (5%)
Hispanic or Latino/a 5 (3%)
Prior service on an institutional review board or equivalent 59 (30%)
Experience interacting directly with human subjects 132 (66%)
Work setting
  University or academic medical center 164 (83%)
  Pharmaceutical or biotechnology 13 (7%)
  Government 13 (7%)
  Other 8 (4%)
Academic rank among those in academic settings
  Professor 88 (54%)
  Associate professor 33 (20%)
  Assistant professor 27 (16%)
  Other 16 (10%)
Degree†
  MD 98 (49%)
  PhD 140 (70%)
  MPH 9 (5%)
  Other 8 (4%)
Location of employment
  United States 95 (48%)
  Canada 6 (3%)
  Europe 71 (36%)
  Asia 22 (11%)
  Other 5 (3%)
Role in study†
  Overall study design 184 (92%)
  Participant recruitment or consent 47 (24%)
  Laboratory analysis 67 (34%)
  Collection of phenotypic information 68 (34%)
  Bioinformatic or statistical analysis 128 (64%)
  Other 22 (11%)
*
Denominators may not equal 200 due to missing data for individual questions
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†
Total may exceed 100%, as respondents could choose more than one category
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Table 2
Characteristics and return-of-results practices of index studies
Number (Percent)
Nature of data acquisition
  Primary data/specimen collection 126 (63%)
  Secondary data/specimen analysis 74 (37%)
Primary Collection Secondary Use
Mode of acquisition of data or specimens* NA
  From those responsible for primary data collection 57 (77%)
  From a public repository 5 (7%)
  Other 12 (16%)
Signed data use agreement† NA
  Yes 49 (67%)
  No 14 (19%)
  Unsure 10 (14%)
If present, data use agreement forbade participant re-identification‡ NA
  Yes 29 (60%)
  No 9 (19%)
  Unsure 10 (21%)
Method to link data/specimens to individual identifiers§
  Directly labeled with identifiers 3 (2%) 0 (0%)
  Linked to identifiers with code 109 (87%) 30 (67%)
  No link to identifiers 9 (7%) 12 (27%)
  Other 3 (2%) 3 (7%)
  Unsure 2 (2%) 0 (0%)
Study has previously returned individual genetic test results to participant(s)**
  Yes 7 (6%) 0 (0%)
  No 107 (91%) 32 (97%)
  Unsure 3 (3%) 1 (3%)
Study has plans to return individual genetic test results to participant(s) ††,‡‡
  Yes 2 (2%) 0 (0%)
  No 103 (94%) 33 (100%)
  Unsure 5 (5%) 0 (0%)
NA, Not applicable
*
Secondary analysis, n=74
†
Secondary analysis, n=73
‡
Secondary analysis, n=48
§
Primary analysis, n=126; secondary analysis, n=45
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**
Primary analysis, n=117, secondary analysis, n=33
††
Primary analysis, n=110, secondary analysis, n=33
‡‡
Among studies that had not previously returned results to individual participants
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